EXAGEN INC. Cost of Revenue
EXAGEN INC. (XGN) reported Cost of Revenue of $400.00 thousand for the 3-month period ending 2019-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2020-11-10
- EXAGEN INC. cost of revenue for the quarter ending 2019-09-30 was $400.00K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 9 month |
|---|---|---|
| 2019-09-30 | $400.00K 10-Q · filed 2020-11-10 | $1.10M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |